Stockscreener 앱 받기
19.28
0.94%
0.18
시간 외 거래:
19.05
-0.23
-1.19%
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
Apellis Pharmaceuticals (APLS) Reports Promising Empaveli Data - GuruFocus
Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction - Seeking Alpha
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report? - Yahoo Finance
Sobi and Apellis data underscore Aspaveli potential - The Pharma Letter
Apellis Pharmaceuticals, Inc. and Sobi Announce EMPAVELI®? (Pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN - marketscreener.com
Apellis Pharmaceuticals, Sobi Report Empaveli's Sustained Efficacy at 1 Year in Phase 3 Study - marketscreener.com
Apellis Pharmaceuticals (APLS) Reports Promising Phase 3 Study Results for EMPAVELI | APLS Stock News - GuruFocus
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Susta - GuruFocus
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed - GlobeNewswire
High Growth Tech Stocks To Watch In The US June 2025 - Yahoo Finance
Apellis Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | APLS Stock News - GuruFocus
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Why Apellis Pharmaceuticals, Inc. (APLS) Skyrocketed On Monday - Yahoo Finance
Wells Fargo & Company Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Up 7.7% Following Analyst Upgrade - Defense World
These 10 Stocks Blew Past Expectations - Insider Monkey
Wells Fargo Adjusts Price Target for Apellis (APLS) to $29 | APLS Stock News - GuruFocus
Wells Fargo raises Apellis Pharmaceuticals stock price target to $29 By Investing.com - Investing.com Canada
Apellis Pharmaceuticals (APLS) Receives Price Target Boost from Wells Fargo | APLS Stock News - GuruFocus
Wells Fargo Adjusts Price Target on Apellis (APLS) Amid Product Launch Anticipation | APLS Stock News - GuruFocus
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,578 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals Insiders Sell US$3.1m Of Stock, Possibly Signalling Caution - simplywall.st
(APLS) Long Term Investment Analysis - news.stocktradersdaily.com
Equities Analysts Offer Predictions for APLS Q2 Earnings - Defense World
SHAREHOLDER ALERT: Potential Recovery for Apellis Pharmaceuticals, Inc. (APLS) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
Nuveen Asset Management LLC Has $15.67 Million Stock Position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Citigroup Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 17 Analysts - Benzinga
APLS: Citigroup Lowers Price Target for Apellis Pharmaceuticals | APLS Stock News - GuruFocus
Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Grow - GuruFocus
Apellis (APLS) Target Price Reduced by Citi Amidst Adjusted Growth Outlook | APLS Stock News - GuruFocus
How the (APLS) price action is used to our Advantage - news.stocktradersdaily.com
Apellis Pharmaceuticals Stock: Have Some Patience (NASDAQ:APLS) - Seeking Alpha
Captrust Financial Advisors Buys Shares of 12,629 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Mizuho Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $20.00 - Defense World
Northern Trust Corp Has $17.46 Million Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 12-Month Low Following Analyst Downgrade - Defense World
Mizuho Lowers Price Target for Apellis Pharmaceuticals (APLS) | - GuruFocus
Apellis (APLS) Faces Price Target Cut as Challenges Persist | AP - GuruFocus
Transcript : Apellis Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 08 - marketscreener.com
Mizuho Securities Adjusts Apellis Pharmaceuticals Price Target to $20 From $30, Maintains Neutral Rating - marketscreener.com
HC Wainwright Has Negative Estimate for APLS Q2 Earnings - Defense World
Wedbush Cuts Earnings Estimates for Apellis Pharmaceuticals - Defense World
William Blair Issues Pessimistic Forecast for APLS Earnings - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Rating Lowered to Outperform at Raymond James - Defense World
What is HC Wainwright’s Forecast for APLS Q1 Earnings? - Defense World
Apellis Pharmaceuticals Stumbles Over Funding And Sales Hurdles - Finimize
Wells Fargo & Company MN Sells 133,752 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Royal Bank of Canada Issues Pessimistic Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Robert W. Baird Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
APLS: Apellis Pharmaceuticals Stock Downgraded by B of A Securit - GuruFocus
B of A Securities Downgrades Apellis Pharmaceuticals (BIT:1APLS) - Nasdaq
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Pri - GuruFocus
Sector Update: Health Care - marketscreener.com
Raymond James Downgrades Apellis Pharmaceuticals (APLS) with Price Target Cut | APLS Stock News - GuruFocus
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down - MSN
1.21%
1.51%
자본화:
|
볼륨(24시간):